| 双向短缺:基本药物政策的制度分析——兼评“新医改”方案的缺陷 | |
| 胡颖廉 ; 薛澜 ; 刘宗锦 ; Yinglian Hu ; Lan Xue ; Zongjin Liu | |
| 2010-06-07 ; 2010-06-07 | |
| 关键词 | 基本药物制度 医药卫生体制 制度分析 双向短缺 “新医改”方案 essential drug policy health care system institutional analysis dual shortages new health care plan R197.1 |
| 其他题名 | Dual Shortages:An Institutional Analysis of Essential Drug Policy-On the New Health Care Plan in China |
| 中文摘要 | "新医改"方案明确提出基本药物制度的设想,引起学者、官员和业界人士的争议。本文试图回答的问题是:基本药物制度在中国实行会遭遇哪些制度障碍?以政治经济学的制度主义为范式,通过综述有关医药卫生体制改革的代表性文献,系统归纳出基本药物制度分析框架。提出当前存在廉价基本药物短缺和同品种高价商品名药泛滥两方面问题。围绕方案所提出政策设计,按照药品生产、定价、招标采购、使用和付费的逻辑划分,分析了制药行业过度竞争、"以药养医"等制约因素,以及采购、报销等配套政策,系统论述了基本药物存在生产(配送)环节供给短缺和使用(招标)环节具有需求短缺的双向短缺问题。在此基础上,得出结论和政策建议。; The essential drug policy in the new health care plan has attracted controversial attention throughout the country.The key question in this research is the following:how do institutional elements affect the performance of a essential drug policy in China? Based on an institutional analysis paradigm and the previous literature on the China health care system,an analytical framework specific to a essential drug policy is proposed.After dividing the four steps in a essential drug life cycle,including manufacture,pricing,procurement,and prescription,the over-competitive pharmaceutical market and"Yi Yao Yang Yi"are deemed to be crucial obstacles;other policy designs,for instance reimbursement,are also introduced.These elements finally lead to the dilemma of dual shortages of essential drugs in China on both the supply and demand sides.Concluding remarks and policy suggestions are offered. |
| 语种 | 中文 ; 中文 |
| 内容类型 | 期刊论文 |
| 源URL | [http://hdl.handle.net/123456789/38235]  |
| 专题 | 清华大学 |
| 推荐引用方式 GB/T 7714 | 胡颖廉,薛澜,刘宗锦,等. 双向短缺:基本药物政策的制度分析——兼评“新医改”方案的缺陷[J],2010, 2010. |
| APA | 胡颖廉,薛澜,刘宗锦,Yinglian Hu,Lan Xue,&Zongjin Liu.(2010).双向短缺:基本药物政策的制度分析——兼评“新医改”方案的缺陷.. |
| MLA | 胡颖廉,et al."双向短缺:基本药物政策的制度分析——兼评“新医改”方案的缺陷".(2010). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论